Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
2020-12-01 · Moleculin Biotech, Inc. · original moleculin.com ↗
HOUSTON, Dec. 1, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066. The designation entitles Moleculin to receive a transferrable Priority Review Voucher (PRV) upon New Drug Approval (NDA) for each of three indications, including diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor.
The release as fetched from its publisher. moleculin.com ↗